PrecizionIQ: Making Prenatal Diagnostics More Accessible Through Metabolomics

Problem

Prenatal screening plays a critical role in identifying chromosomal abnormalities and pregnancy-related complications, but access to advanced diagnostic tests can be constrained by cost, infrastructure and the need for specialised testing. PrecizionIQ aims to make early risk detection more affordable and accessible through non-invasive, biomarker-based diagnostic solutions.

Product

PrecizionIQ is developing metabolomics-based prenatal diagnostics using three formats: dried blood spot testing analysed through liquid chromatography–mass spectrometry (LC-MS), ELISA-based laboratory testing and lateral flow assay (LFA) rapid tests. The company aims to combine the analytical depth of advanced diagnostics with simpler, lower-cost testing formats for wider adoption.

The startup has filed a Patent Cooperation Treaty (PCT) application for its metabolomics-based diagnostic methodology for prenatal chromosomal abnormalities. In 2026, it also secured a Golden Ticket at the PanIIT Bangalore Summit's Bharat Ke Super Founders pitchathon, gaining recognition for its diagnostic innovation. Its products remain at the development and validation stage, based on publicly available information.

PrecizionIQ's founding team includes Dr. Murli Manohar, Dr. Pedro Rodrigues, Dr. Kamal Tyagi, Amit Kumar and Anurag Dikshit. The team brings together expertise directed towards developing biomarker-led diagnostic technologies and translating scientific research into accessible healthcare solutions.

PrecizionIQ has reported securing $210,000 in pre-seed funding from a US-based angel investor to support product development, clinical validation and regulatory groundwork. The company is currently reported to be pre-revenue, with funding directed towards advancing its diagnostic platform towards commercialisation.

The immediate priority is to commercialise its prenatal diagnostic solutions for chromosomal abnormalities and preeclampsia, subject to clinical validation and regulatory requirements. The company also plans to explore partnerships with diagnostic laboratories and healthcare providers, while extending its metabolomics platform to areas such as cancer detection.

PrecizionIQ is working to bridge the gap between advanced biomarker science and affordable prenatal screening. If successfully validated and commercialised, its diagnostic formats could help extend access to early risk assessment across hospitals, diagnostic laboratories and underserved communities.

Disclaimer: This profile is independent editorial content based on publicly available information and company disclosures reviewed as of October 2026. The profile does not constitute medical, clinical or investment advice.